1. Why is cholesterol of interest for metabolic health and disease? (0:07)
2. Is cellular cholesterol toxicity and type 2 diabetes risk supported by clinical findings? (0:50)
3. Are there data that explain the incidence of increased type 2 diabetes risk with statin therapy? (1:27)
4. How does pitavastatin differ in having a favorable impact on metabolic health? (3:18)
View the full article here.
Speaker disclosures: Jeffrey S Elmendorf has nothing to declare in relation to this video interview.
Support: The publication of this video was supported by Kowa Pharmaceuticals America who was given the opportunity to review the video for scientific accuracy before publication. Any resulting changes were made at the author’s/authors’ discretion.